Gamma Knife surgery for the treatment of 5 to 15 metastases to the brain
- 1 June 2013
- journal article
- Published by Journal of Neurosurgery Publishing Group (JNSPG) in Journal of Neurosurgery
- Vol. 118 (6), 1250-1257
- https://doi.org/10.3171/2013.2.jns121213
Abstract
It has been generally accepted that Gamma Knife surgery (GKS) is an effective primary or adjunct treatment for patients with 1-4 metastases to the brain. The number of studies detailing the use of GKS for 5 or more brain metastases, however, remains minimal. The aim of the current retrospective study was to elucidate the utility of GKS in patients with 5-15 brain metastases. Patients were chosen for GKS based on prior MRI of these metastatic lesions and a known primary cancer diagnosis. Magnetic resonance imaging was used post-GKS to assess tumor control; patients were also followed up clinically. Overall survival (OS) from the date of GKS was used as the primary end point. Statistical analysis was performed to identify prognostic factors related to OS. Between 2003 and 2012, 96 patients were treated for a total of 704 metastatic brain lesions. The histology of these lesions varied among non-small cell lung cancer (NSCLC), breast cancer, melanoma, renal cancer, and other more rare carcinomas. At the initial treatment, 18 of the patients (18.8%) were categorized in Recursive Partitioning Analysis (RPA) Class 1 and 77 (80.2%) in RPA Class 2; none were in RPA Class 3. The median number of treated lesions was 7 (mean 7.13), and the median planned treatment volume was 6.12 cm(3) (range 0.42-57.83 cm(3)) per patient. The median clinical follow-up was 4.1 months (range 0.1-40.70 months). Actuarial tumor control was calculated to be 92.4% at 6 months, 84.8% at 12 months, and 74.9% at 24 months post-GKS. The median OS was found to be 4.73 months (range 0.4-41.8 months). Multivariate analysis demonstrated that RPA class was a significant predictor of death (HR = 2.263, p = 0.038). Number of lesions, tumor histology, Graded Prognostic Assessment score, prior whole-brain radiation therapy, prior resection, prior chemotherapy, patient age, patient sex, controlled primary tumor, extracranial metastases, and planned treatment volume were not significant predictors of OS. In patients with 5-15 brain metastases at presentation, the number of lesions did not predict survival after GKS; however, the RPA class was predictive of OS in this group of patients. Gamma Knife surgery for such patients offers an excellent rate of local tumor control.Keywords
This publication has 34 references indexed in Scilit:
- Treatment of Five or More Brain Metastases With Stereotactic RadiosurgeryInternational Journal of Radiation Oncology*Biology*Physics, 2012
- Subclassification of Recursive Partitioning Analysis Class II Patients With Brain Metastases Treated RadiosurgicallyInternational Journal of Radiation Oncology*Biology*Physics, 2012
- Therapeutic Effect of Gamma Knife Radiosurgery for Multiple Brain MetastasesJournal of Korean Neurosurgical Society, 2011
- The role of stereotactic radiosurgery in the management of patients with newly diagnosed brain metastases: a systematic review and evidence-based clinical practice guidelineJournal of Neuro-Oncology, 2009
- New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)European Journal of Cancer, 2009
- Gamma Knife Radiosurgery for Ten or More Brain MetastasesJournal of Korean Neurosurgical Society, 2008
- Stereotactic radiosurgery alone versus resection plus whole‐brain radiotherapy for 1 or 2 brain metastases in recursive partitioning analysis class 1 and 2 patientsCancer, 2007
- Gamma knife surgery for brain metastases from lung cancerJournal of Neurosurgery, 2005
- Whole brain radiation therapy with or without stereotactic radiosurgery boost for patients with one to three brain metastases: phase III results of the RTOG 9508 randomised trialThe Lancet, 2004
- Comparison of three treatment options for single brain metastasis from lung cancerInternational Journal of Cancer, 2000